2024-511172-33-00Active, not recruitingPhase 1/2
A Multicenter, Long-term, Follow-up Study to Investigate the Safety and Durability of Response Following Dosing of an Adeno-associated Viral Vector (FLT201) in Subjects with Gaucher Disease (GALILEO-2)
Source: EU CTIS (euclinicaltrials.eu) · Last updated 5 May 2026
Brief summary (registry, in English)
To assess the long-term safety of FLT201 in participants with Gaucher disease type 1.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 1 (estimated)
- First submitted
- 15 Feb 2024
- Start date
- 10 May 2024
- Lead sponsor
- Spur Therapeutics Limited
- Diseases
- Gaucher disease
- EU CT number
- 2024-511172-33-00
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 1
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Other
- Not applicable.
Who the study is looking for
- Participants who have previously received FLT201 (including those who may have required recommencement or initiation of ERT/substrate reduction therapy [SRT]).
- Participants able to give full informed consent and able to comply with all requirements of the trial.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital QuirónSalud Zaragoza Coordinator of this site? Confirm its status | Zaragoza | Spain | Active, not recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.